NO20015247L - Glysinspaltingssysteminhibitorer som potensielle antipsykotika - Google Patents

Glysinspaltingssysteminhibitorer som potensielle antipsykotika

Info

Publication number
NO20015247L
NO20015247L NO20015247A NO20015247A NO20015247L NO 20015247 L NO20015247 L NO 20015247L NO 20015247 A NO20015247 A NO 20015247A NO 20015247 A NO20015247 A NO 20015247A NO 20015247 L NO20015247 L NO 20015247L
Authority
NO
Norway
Prior art keywords
glycemic
system inhibitors
potential
antipsychotics
potential antipsychotics
Prior art date
Application number
NO20015247A
Other languages
English (en)
Other versions
NO20015247D0 (no
Inventor
Michael Arlt
Gerd Bartoszyk
Original Assignee
Merck Patent Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent Gmbh filed Critical Merck Patent Gmbh
Publication of NO20015247D0 publication Critical patent/NO20015247D0/no
Publication of NO20015247L publication Critical patent/NO20015247L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/145—Amines having sulfur, e.g. thiurams (>N—C(S)—S—C(S)—N< and >N—C(S)—S—S—C(S)—N<), Sulfinylamines (—N=SO), Sulfonylamines (—N=SO2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Oppfinnelsen vedrører inhibitorer for glysinspaltingssystemet og deres anvendelse som potensielle antipsykotiske midler. Oppfinnelsen vedrører dessuten en fremgangsmåte for behandling av mennesker som har psykose, psykose forbundet med en sykdom, schizofreni, Alzheimers sykdom eller andre beslektede psykotiske forstyrrelser.
NO20015247A 1999-04-29 2001-10-26 Glysinspaltingssysteminhibitorer som potensielle antipsykotika NO20015247L (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US13164799P 1999-04-29 1999-04-29
EP99108480 1999-04-30
PCT/EP2000/003456 WO2000066110A1 (en) 1999-04-29 2000-04-17 Glycine cleavage system inhibitors as potential antipsychotics

Publications (2)

Publication Number Publication Date
NO20015247D0 NO20015247D0 (no) 2001-10-26
NO20015247L true NO20015247L (no) 2001-10-26

Family

ID=56290006

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20015247A NO20015247L (no) 1999-04-29 2001-10-26 Glysinspaltingssysteminhibitorer som potensielle antipsykotika

Country Status (12)

Country Link
US (1) US6395780B1 (no)
EP (1) EP1185259A1 (no)
JP (1) JP2002543124A (no)
KR (1) KR20020008167A (no)
AU (1) AU4748100A (no)
BR (1) BR0010151A (no)
CA (1) CA2372073A1 (no)
CZ (1) CZ20013786A3 (no)
MX (1) MXPA01010933A (no)
NO (1) NO20015247L (no)
PL (1) PL353180A1 (no)
WO (1) WO2000066110A1 (no)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1565185A4 (en) * 2002-11-07 2011-01-05 Technion Res & Dev Foundation NEUROPROTECTIVE IRON CHELATORS AND PHARMACEUTICAL COMPOSITIONS THEREWITH
GB2398497A (en) * 2003-02-19 2004-08-25 Walcom Animal Science Composition for improving immunity of animals
WO2004093910A1 (ja) * 2003-04-22 2004-11-04 Astellas Pharma Inc. ＰＰＡＲδアゴニストによる脳神経変性疾患治療剤
WO2005039548A2 (en) * 2003-10-15 2005-05-06 Probiodrug Ag Use of effectors of glutaminyl and glutamate cyclases
EP1686973A4 (en) 2003-11-25 2009-03-25 Technion Res & Dev Foundation COMPOSITIONS AND METHODS FOR THE TREATMENT OF CARDIOVASCULAR DISEASES AND DISEASES
US8097608B2 (en) * 2003-11-25 2012-01-17 Technion Research And Development Foundation Ltd. Methods for treatment of cardiovascular disorders and diseases
JP2007517049A (ja) * 2003-12-29 2007-06-28 マクデビット、ジェイソン 再発性病状を治療するための組成物および方法
EP1706104A2 (en) * 2004-01-13 2006-10-04 Omega Bio-Pharma (I.P.2) Limited Methods for treating stress and affecting biological immune systems using a cysteamine compound
JP2005232148A (ja) * 2004-02-03 2005-09-02 Technion Research & Development Foundation Ltd 神経保護剤としてプロパルギルアミンの使用
JP4954864B2 (ja) 2004-04-01 2012-06-20 カーディオム ファーマ コーポレイション イオンチャネル調節化合物のプロドラッグおよびその使用
ITMI20040876A1 (it) * 2004-04-30 2004-07-30 Univ Degli Studi Milano Inibitori delle istone deacetilasi-hdac-quali agenti ipolipidemizzati per la terapia e la prevenzione dell'arteriosclerosi e malattie cardiovascolari
JP2008545663A (ja) * 2005-05-27 2008-12-18 クイーンズ ユニバーシティ アット キングストン タンパク質フォールディング障害の治療
FR2890563B1 (fr) * 2005-09-09 2007-10-19 Servier Lab Nouvelle association entre l'agomelatine et un agent thymoregulateur et les compositions pharmaceutiques qui la contiennent
US8263655B2 (en) * 2005-10-06 2012-09-11 Technion Research And Development Foundation Ltd Methods for treatment of renal failure
KR200453511Y1 (ko) * 2009-12-29 2011-05-13 한국강성(주) 마이크로 유에스비 커넥터 플러그
BR112012019374B1 (pt) 2010-02-03 2022-01-11 Pharma Two B Ltd Composição farmacêutica oral e uso de um agente ativo para a preparação de uma composição farmacêutica oral para o tratamento de doenças neurodegenerativas
WO2013120086A1 (en) * 2012-02-10 2013-08-15 Whitehead Institute For Biomedical Research Inhibition of the glycine cleavage system for treatment of cancer

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9218709D0 (en) * 1992-09-04 1992-10-21 Salim Aws S M Biologically active health formulation
EP1067922A1 (en) * 1998-03-30 2001-01-17 The Endowment For Research In Human Biology, Inc. Agents and methods for modulation of zinc transfer by metallothionein

Also Published As

Publication number Publication date
MXPA01010933A (es) 2002-06-21
CA2372073A1 (en) 2000-11-09
NO20015247D0 (no) 2001-10-26
PL353180A1 (en) 2003-11-03
US6395780B1 (en) 2002-05-28
EP1185259A1 (en) 2002-03-13
CZ20013786A3 (cs) 2002-02-13
AU4748100A (en) 2000-11-17
JP2002543124A (ja) 2002-12-17
BR0010151A (pt) 2002-06-11
KR20020008167A (ko) 2002-01-29
WO2000066110A1 (en) 2000-11-09

Similar Documents

Publication Publication Date Title
NO20015247L (no) Glysinspaltingssysteminhibitorer som potensielle antipsykotika
HK1063012A1 (en) Napthoquinone derivatives as inhibitors of tau aggregation for the treatment of alzheimer&#39;s and related neurodegenerative disorders
NO2016007I1 (no) Susoktokog
ES2170104T3 (es) Inhibidores de la produccion de proteinas de beta-amiloide.
DE60009511D1 (de) Nematizide trifluorbutene
NO20025450D0 (no) Ny farmasöytisk sammensetning
DE60327999D1 (de) Azolylaminoazine als inhibitoren von proteinkinasen
DE60314603D1 (de) Zusammensetzungen brauchbar als protein-kinase- inhibitoren
GB0117645D0 (en) Therapeutic stratergies for prevention and treatment of alzheimers disease
CY1112932T1 (el) Αναστολεις sμαd7 για τη θεραπευτικη αγωγη ασθενειων του κνς
ATE482936T1 (de) Als b-sekretase (bace)-hemmer nützliche 2-amino- chinazolinderivate
BRPI0407662B8 (pt) derivados do ácido 1-fenilalcanocarboxílico para o tratamento de doenças neurodegenerativas
DE60312736D1 (de) 1,2,4-triaminobenzolderivate zur behandlung von erkrankungen des zentralnervensystems
NO20082679L (no) Sammensetning og fremgangsmate for a behandle CNS lidelser
BG106509A (en) Preparative form
DK1553985T3 (da) Biphenyler som billeddannelsesmiddel i forbindelse med Alzheimers sygdom
DE60108626D1 (de) Verwendung von 5-thio, sulfinyl- und sulfonylpyrazolo 3,4-b] pyridinen als cyclin-abhängige kinase-hemmer
NO20044530L (no) Fremgangsmate for behandling av kognitive forstyrrelser
BR0314180A (pt) Aminoéteres substituìdos para o tratamento da doença de alzheimer
BR0012921A (pt) Compostos calcilìticos
ATE425756T1 (de) Verwendung von carbamazepinderivaten zur behandlung von agitatio in demenspatienten
BR0314541A (pt) Tratamento de demência e doença de parkinson
WO2004034062A3 (en) Use of cap-1 for the therapy of asthma
SE0202608D0 (sv) New sequences
DE60321443D1 (de) Screening-verfahren für eine prophylaktische und therapeutische Substanz für eine Nierenerkrankung

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application